CANTANHEDE, Portugal, Dec. 22, 2025 /PRNewswire/ -- Mondego Bio, a clinical-stage biotechnology company developing next-generation small-molecule immuno-oncology therapies, today announced the formal selection of its lead clinical candidate, ZE00-0388, a highly selective inhibitor of...
Hence then, the article about mondego bio announces selection of a ptpn2 inhibitor clinical candidate and targets first in human trials in h1 2026 was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Mondego Bio Announces Selection of a PTPN2 Inhibitor Clinical Candidate and Targets First-in-Human Trials in H1 2026 )
Also on site :
- Here’s how 2025 killed old-school diplomacy
- Quantum Computing in Financial Services Market Set to Reach USD 6.3 Billion by 2032 as Banks Move from Experimentation to Quantum Advantage .. DataM Intelligence
- The Board of Directors of SciBase resolves on a previously communicated rights issue of shares of approximately SEK 83 million